ACC: New Anticoagulants Signal Start of Post-Warfarin Era

http://www.medpagetoday.com/MeetingCoverage/ACC/19036

ATLANTA -- Atrial fibrillation is both a major stroke risk and a looming public health problem since the risk of afib increases with age, and the standard treatment, warfarin, is often a clinical management challenge. But a number of investigational therapies suggest that a post-warfarin era is beginning.

In this MedPage Today InFocus™ report, American College of Cardiology president Ralph Brindis, MD, of the University of California San Francisco, says two new compounds, betrixaban and dabigatran, have "raised the threshold" for anticoagulation therapy.

Category:

News & Politics

Tags:

• medicine
• health